MIT Researchers Develop Injectable Mini Livers for Future Liver Disease Treatment
For many people who suffer from liver disease, a liver transplant is usually the only life-saving treatment. But when organ donors are fewer, many patients become too ill while waiting for a suitable organ donor. Researchers at the Massachusetts Institute of Technology (MIT) have now invented a unique approach that could one day provide patients another option—injectable “mini livers,” also called satellite livers, that help restore liver function without replacing the original organ.
The technology is at an experimental stage where it has only been tested in mice, but early results tell us that this treatment could support patients with liver failure while they wait for a transplant; it can also be used to reduce the chances of needing a transplant.
A Different Approach to Treating Liver Failure
Instead of replacing a damaged liver, the researchers add healthy liver tissue elsewhere in the body. The engineered tissue grafts act like “ helper” organs, which help perform the liver’s many basic functions while the patient’s own liver remains in place.
The liver has around 500 important functions, which include producing blood-clotting proteins, breaking down medicines and toxins, processing nutrients, and removing harmful substances from the bloodstream. These are usually done by specialised liver cells called hepatocytes. It is when hepatocytes are damaged that liver failure can take place.
Building an Injectable Mini Liver
The scientists at MIT did try transplanting hepatocytes before; however, the cells failed to survive because they couldn’t connect with the body’s blood supply quickly.
To solve this issue, the team created tiny hydrogel microspheres using a microfluidic device. The soft, gel-like particles are mixed in with healthy hepatocytes before being injected into the body.
The hydrogel becomes stable once injected, which allows the liver cells to stay together and slowly form functional tissue. This structure also helps the cells to connect with nearby blood vessels, which helps them receive oxygen and other nutrients needed in order to survive.
The researcher also added fibroblasts, which are cells that promote tissue growth and encourage the formation of new blood vessels around the implanted liver cells.
Minimally Invasive and Precisely Delivered
Another important part of the research was developing an ultrasound-guided injection technique. Instead of requiring surgery, doctors can accurately inject the engineered liver tissue into fatty tissue inside the abdomen using ultrasound guidance. The same imaging technique can later be used to monitor the implanted tissue and check whether it remains healthy.
Promising Results in Animal Studies
The experiment was tested in mice, and the injected hepatocytes successfully formed stable mini liver grafts within a few weeks. New blood vessels grew into the tissue, which allowed the transplanted cells to work like normal tissue.
The cells remained active for at least eight weeks, which led to the production of many important liver proteins and enzymes throughout the study. The findings explained that the engineered grafts could provide long-term support, although more research is needed before going into human trials.
What Happens Next?
The researchers explain that this technology is not yet ready for clinical use. One of the biggest issues is preventing the body’s immune system from rejecting the transplanted liver cells. Patients would likely require immunosuppressive medications, although scientists are also exploring ways to protect the implanted cells without long-term drug therapy.
Despite these challenges, the study represents an important advance in regenerative medicine and tissue engineering. By combining hepatocytes, hydrogel biomaterials, supportive cells, and less invasive delivery techniques, researchers have shown a new way to restore liver function without replacing the entire organ.
If future studies in humans are successful, injectable satellite livers could become a valuable bridge for patients waiting for a transplant and could offer a new treatment option for people living with advanced liver disease.
